TABLE 3.
Multivariable | HR for OS death | 95% CI Lower | 95% CI Upper | p |
---|---|---|---|---|
(A) Radical‐intent surgery | ||||
Age | 1.002 | 0.987 | 1.017 | 0.775 |
Sex (female) b | 0.888 | 0.698 | 1.131 | 0.336 |
CCI 1 | 0.951 | 0.697 | 1.296 | 0.748 |
CCI 2 | 1.029 | 0.721 | 1.469 | 0.876 |
CCI 3+ | 1.099 | 0.751 | 1.608 | 0.628 |
VTE >1 year before PC dg | 0.870 | 0.472 | 1.604 | 0.655 |
VTE ≤1 year before PC dg | 1.902 | 0.589 | 6.145 | 0.283 |
VTE after PC dg | 2.571 | 1.791 | 3.691 | <0.001 |
Chemo‐ and/or radiation therapy c | ||||
0–12 months | 0.491 | 0.295 | 0.818 | 0.006 |
>12 months | 1.042 | 0.7622 | 1.423 | 0.798 |
(B) Palliative treatment | ||||
Age | 1.026 | 1.023 | 1.030 | <0.001 |
Sex (female) b | 0.900 | 0.843 | 0.962 | 0.002 |
CCI 1 | 1.038 | 0.953 | 1.131 | 0.397 |
CCI 2 | 1.028 | 0.934 | 1.131 | 0.572 |
CCI 3+ | 1.239 | 1.130 | 1.358 | <0.001 |
VTE >1 year before PC dg | 1.061 | 0.905 | 1.242 | 0.467 |
VTE ≤1 year before PC dg | 1.857 | 1.576 | 2.188 | <0.001 |
VTE after PC dg | 2.111 | 1.875 | 2.377 | <0.001 |
Chemo‐ and/or radiation therapy c | ||||
0–12 months | 0.633 | 0.578 | 0.693 | <0.001 |
>12 months | 0.863 | 0.726 | 1.025 | 0.092 |
One radical‐intent surgery patient who underwent oncological treatment for pancreatic cancer over 1 year before the radical‐intent surgery was excluded from the model. In addition, radical surgery patients who underwent oncological treatment only over 1 year after surgery were considered no chemotherapy or no radiation therapy in this model. Patients who had died at the start of the follow‐up period were excluded from this model (n = 25 among the palliative treatment group).
A minor deviance from the proportional hazard assumption for sex was ignored.
The time axis was split to account for deviances from the proportional hazard assumption. Chemo‐ and/or radiation therapy and VTE following a pancreatic cancer diagnosis represent time‐dependent variables.
Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; dg, diagnosis; HR, hazard ratio; OS, overall survival; PC, pancreatic cancer; VTE, venous thromboembolism.